Across TCGA pan-cancer cohorts, UTP23 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UTP23 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher UTP23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UTP23 expression acts as an unfavorable survival marker.
CESC, THYM, and UCEC are the cancer types where UTP23 Mutation most reproducibly stratifies survival.